Disturbed B cell homeostasis of B cells in SLE: Delineation of intrinsic signaling abnormalities

• Applicant: Professor Dr. Thomas Dörner
• Subject Area: Rheumatology
• Term: from 2017 to 2021
• Project identifier: Deutsche Forschungsgemeinschaft (DFG) - Project number 390780177

• Final Report Year: 2021

Final Report Abstract

No abstract available

Publications

• (2018). Anti-interleukin-6 signalling therapy rebalances the disrupted cytokine production of B cells from patients with active rheumatoid arthritis. Eur J Immunol 48, 194-203
  Fleischer, S., Ries, S., Shen, P., Lheritier, A., Cazals, F., Burmester, G.R., Dorner, T., and Fillatreau, S.
  
• (2019). Identification and Characterization of Post-activated B Cells in Systemic Autoimmune Diseases. Front Immunol 10, 2136
  Weissenberg, S.Y., Szelinski, F., Schrezenmeier, E., Stefanski, A.L., Wiedemann, A., Rincon- Arevalo, H., Welle, A., Jungmann, A., Nordstrom, K., Walter, J., et al.
  
• (2020). Therapeutic implications of the anergic/postactivated status of B cells in systemic lupus erythematosus. RMD Open 6
  Dorner, T., Szelinski, F., Lino, A.C., and Lipsky, P.E.
  
• (2021). Toll-like receptor signalling in B cells during systemic lupus erythematosus.Nat Rev Rheumatol. 17:98-108
  Fillatreau S, Manfroi B, Dörner T